CN101869559B - Application of gartanin compound in preparing medicaments for treating hyperlipidemia - Google Patents
Application of gartanin compound in preparing medicaments for treating hyperlipidemia Download PDFInfo
- Publication number
- CN101869559B CN101869559B CN200910066864.2A CN200910066864A CN101869559B CN 101869559 B CN101869559 B CN 101869559B CN 200910066864 A CN200910066864 A CN 200910066864A CN 101869559 B CN101869559 B CN 101869559B
- Authority
- CN
- China
- Prior art keywords
- compound
- gartanin
- hyperlipidemia
- cho
- treating hyperlipidemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of a gartanin compound in preparing medicaments for treating hyperlipidemia. An extracting and preparing method of the gartanin compound comprises the following steps of: pulverizing corylus heferopuylla peels and extracting by using 20-25 percent of 30-95 percent alcohol at the temperature of 30-80 DEG C; recovering the alcohol until no alcohol taste exists; extracting by using ethyl acetate; and obtaining the gartanin compound through methods of silica column chromatography, recrystallization, and the like. The compound is a raw material medicine for novel medicine research, mp is 171-172 DEG C, and the productivity reaches 0.4-0.5 percent. The gartanin compound can be applied to preparing medicaments for treating hyperlipidemia.
Description
Technical field
The present invention relates to a kind of medicinal usage of monomeric compound, this compound refers in particular to gartanin compound.
background technology
Gartanin compound Chinese is 1,3,5,8-tetrahydroxy-2,4-bis-(3-methyl-2-butene base)
ketone.From Corylus heterophylla Fisch skin, to extract the separated monomeric compound obtaining.
Fig. 1 is 1,3,5,8-tetrahydroxy-2,4-bis-(3-methyl-2-butene base)
ketone structural formula.
Corylus heterophylla Fisch (Corylus heterophylla Fisch) is a kind for hazel.Hazel (Corylusheterophylla Fish.ex Bess.) is Betulaceae (betulaceae) Corylus (corlus) plant, originates in China, according to textual criticism, has so far the history of more than 6000 year.Because the wild resource of hazel is abundant, what China was more for many years is to utilize wild resource, along with developing rapidly of cultivation, and the continuous developing in market, existing a small amount of cultivation in China some areas in the last few years.At present, hazel in China's cultivation has 12 kinds of Corylus heterophylla Fisch (Corylus heterophylla Fisch), Corylus mandshurica (Corlus mandshurica Batal), cnidocil (Corylus tibetica Batal) etc., all there is distribution on the ground such as more and general ， Liaoning, Jilin, Heilungkiang, Shanxi, Shandong, Henan that wherein distribute with Corylus heterophylla Fisch.Hazel is the fine tree species of fruit material dual-purpose, not only can produce very precious timber, and can produce first-class nut and take the luxury food that its kernel is raw material.The timber of hazel is hard, and texture, color and luster are attractive in appearance, can do small-sized joiner's material, and its seed kernel oil fragrance is edible, is again the raw material of making soap, wax candle and cosmetics.
The botanical character of hazel and growth distribution: hazel is perennial arbor or shrub, and the height of tree is generally 1.5-2m, bark taupe, glossy, 1 year raw branch brown, close raw fine hair; Perula crineous, edge hairiness; Leaf alternate, stipule is little, caducous; Blade circle, wide avette or obovate, most advanced and sophisticated nearly shape or the circle of cutting, shallow splitting, central sliver is longer, gradually sharp, and there is irregular heavy sawtooth at the heart-shaped Huo Jiexing， of base portion edge; Top is truncate, and there is outstanding blade tip in central authorities; Bottle green above leaf, below light green color, lateral vein 3-5 couple, mostly is pinniform vein; Unisexual flower, hermaphroditism, without petal, first leaf is open, staminate inflorescence is cylindrical, sagging amentum, the bract that tool is most, imbricate is arranged, in each bract, there is forked stamen 4-8 piece, flower pesticide is yellow, and female flower and is born near staminate inflorescence, contains in an involucre, only red stigma is outstanding, exposes bud top when open; Nut 1-6, light brown, cluster or Dan Sheng, larger, spherical or oval, the about 1.5cm in footpath, has 2 of phyllarys, shallow splitting, mitriform, the close raw pubescence in outside and setiform body of gland.The florescence 4-5 month, fructescence JIUYUE.Hazel is born in the dry hillside that faces south, hillock, wasteland, roadside and border etc. and locates.Be distributed in Northeast China, North China.
The main component of hazel: the leaf of hazel contains tannin, and have flavone reaction, bark contains tannin; Kernel carbohydrate containing, protein, fat; Fruit contains starch; Ye Shang contains alkaloid.The fatty acid of oil forms Palmic acid, stearic acid, oleic acid and linoleic acid etc.
Hazel has medical value widely: kernel can QI invigorating, appetizing, improving eyesight.For body is empty after being ill, lack of appetite is tired.Be decocted in water for oral dose, consumption 30-60g.The male flower of hazel has antiinflammatory, detumescence, analgesic effect.Can be used for scytitis, cold injury etc.
Hyperlipemia is person in middle and old age's commonly encountered diseases, and main harm is to cause atherosclerosis, and then causes numerous relevant diseases, and wherein modal a kind of mortality disease is exactly coronary heart disease.Serious chylomicronemia can cause acute pancreatitis, is another mortality disease.This disease to the infringement of health be concealment, gradually, carrying out property and general.Its direct infringement is to accelerate systemic atherosclerosis, because the vitals of whole body all will rely on tremulous pulse blood supply, oxygen supply, once tremulous pulse is stopped up by atheromatous plaque, will cause serious consequence.The renal failure that arteriosclerosis causes etc., all closely related with hyperlipemia.Research datas show in a large number, and hyperlipemia is apoplexy, coronary heart disease, myocardial infarction, cardiac sudden death is independent and important risk factor.In addition, hyperlipemia is also an important risk factor that promotes hypertension, impaired glucose tolerance, diabetes.Hyperlipemia also can cause fatty liver, liver cirrhosis, cholelithiasis, pancreatitis, retinal hemorrhage, blind, peripheral vascular disease, limping, hyperuricemia.Also can there are tendon shape, nodositas, palm plane and eye socket around xanthoma, arcus juvenilis etc. in some constitutional and familial hyperlipidemia patient
Hyperlipemia mainly refers to serum total cholesterol (TC) or triglyceride (TG) level is too high and (or) Serum High-Density Lipoprotein-Cholesterol (HDL-C) level is too low.Hyperlipemia is person in middle and old age's commonly encountered diseases and frequently-occurring disease, and along with the raising of people's living standard and the change of living habit, this sick sickness rate obviously increases, and the age of morbidity also shifts to an earlier date to some extent.The caused atherosclerosis of hyperlipemia is to cause the main cause of coronary heart disease, hypertension and cerebrovascular disease, and the whole world approximately has 1,500 ten thousand people to die from cardiovascular diseases and apoplexy every year.So the treatment of hyperlipemia is extremely important, this has caused showing great attention to of the whole mankind.The final purpose for the treatment of hyperlipemia is to suppress arteriosclerotic further developing, thereby prevents the death that caused by cardio-cerebrovascular diseases.
The Western medicine that is used for the treatment of at present hyperlipemia is because it is rapid-action and curative effect is subject to everybody favor certainly, but Western medicine has toxic and side effects in various degree, and Chinese medicine is in treatment hyperlipemia, prevent that from there is unique advantage the aspects such as cardiovascular and cerebrovascular disease generation, its curative effect certainly, continue, side effect is little, is that Western medicine institute is incomparable.Particularly, aspect differentiation of symptoms and signs for classification of syndrome, embodied the flexible prescription of the traditional Chinese medical science, the treatment characteristic of giving treatment in accordance with the patient’s individuality.Modern medicine man generally believes genus deficiency in origin and excess in superficiality for the understanding of hyperlipemia, blood stasis, and the turbid category of expectorant, ahyperlipoidemia name of disease in Chinese medicine, clinical syndrome differentiation is attributed to caused by liver and kidney deficiency more, and insufficiency of the spleen expectorant is turbid, qi depression to blood stasis.Large multiplex liver and kidney tonifying during treatment, invigorating the spleen and benefiting QI, nourishing YIN and benefiting blood, blood circulation promoting and blood stasis dispelling, clearing away heat and loosing the bowels, these medicines eliminate indigestion and phlegm.
In recent years, researcher both domestic and external is carrying out a large amount of work aspect the research of exploring antilipemic Chinese herbal medicine, bibliographical information flavonoid and
ketone compounds has hypolipidemic activity, in view of contain more rich flavone compound in Hazel Leaves, in the separation and Extraction process of compound, finds
ketone compounds Gartanin is mainly distributed in ethyl acetate part.
In Corylus heterophylla Fisch skin, contain a large amount of flavone compounds, aspect reduction hyperlipidemia, there is stronger biological activity.Gartanin compound exploitation in resourceful Corylus heterophylla Fisch skin is become to atorvastatin, and the hyperlipemic patients crowd for vast, is with a wide range of applications.
At present, report is not seen in the application of relevant gartanin compound in preparation treatment hyperlipidemia medicine.
Summary of the invention
The object of this invention is to provide the application of gartanin compound in preparation treatment hyperlipidemia medicine.
The preparation method of gartanin compound has had a lot of reported in literature, the invention provides a kind of employing Corylus heterophylla Fisch skin extraction preparation gartanin compound extraction process for purification to be:
A. Corylus heterophylla Fisch corium farinosum is broken, under 30-80 ℃ of condition, with 20-25, doubly measure 30%-95% ethanol extraction 3 times, be respectively 3h, 2h, 1h at every turn, filter merge extractive liquid;
B. on extracting solution step a being obtained, reclaim ethanol to without alcohol taste, be extracted with ethyl acetate, reclaim extract and obtain ethyl acetate extract.
C. ethyl acetate extract step b. being obtained is through silica gel column chromatography, 1) and petroleum ether-acetone (25-1: 1) eluant is chloroform-methanol (15-1:, collect gartanin compound part, reclaim solvent to dry, Gossypol recrystallized from chloroform obtains yellow acicular crystal product, mp 171-172 ℃, productive rate reaches 0.4%-0.5%.
Technical scheme of the present invention is:
The application of gartanin compound in preparation treatment hyperlipidemia medicine.
When the present invention for the preparation for the treatment of hyperlipidemia medicine time, its oral or parenteral, all safe, in oral situation, it can any conventionally form administration, as powder, granule, tablet, capsule, pill, solution, suspension, syrup, buccal tablets, sublingual lozenge etc.: when this medicine parenteral, can take any conventionally form, such as injection: as intravenous injection, ointment, suppository, percutaneous dosing, inhalant etc.
It is to form together with the excipient of effective ingredient monomer or effective ingredient and solid or liquid that the present invention prepares the medicine for the treatment of hyperlipidemia, the excipient of solid used herein or liquid is well known in the art, lift several object lessons below, powder is powder agent for oral administration, its excipient has lactose, starch, paste essence, calcium carbonate, synthetic or puritan filler aluminum, magnesium oxide, magnesium stearate, sodium bicarbonate, dry yeast etc.; The excipient of solution has water, glycerol, propylene glycol, simple syrup, ethanol, ethylene glycol, Polyethylene Glycol, Sorbitol etc.; The excipient of ointment can be used fatty oil, and agnolin, vaseline, glycerol, Cera Flava, wood are cured, white oil, resin, senior water-repelling agent or the hydrophilizing agent being combined into such as cured.
The invention has the beneficial effects as follows, the gartanin compound that Corylus heterophylla Fisch skin obtains belongs to effective ingredient, and its medicinal usage belongs to first to be found, for treatment hyperlipidemia has been found new precursor compound.
The dosage of effective ingredient can be according to taking mode, and patient's age and body weight and coincident with severity degree of condition change with other similar factor, and oral dose is: 20～100mg/ time, take every day for 1～2 time: inject 10～30mg/ time, once a day.
The specific embodiment
The present invention can further illustrate by experimental example below.
The preliminary test of experimental example one, gartanin prevention and treatment hyperlipidemia
1 experiment material
Animal
ICR mice, 84, male 60, female 24, body weight 18-20g.Purchased from Jilin University's preclinical medicine institute zoopery center, the animal quality certification number: SCXK-(Ji)-2003-0001.
Medicine and reagent
XUEZHIKANG JIAONANG: specification 300mg/ grain, lot number 20060305, Beijing WBL Peking University Biotech Co., Ltd produces;
Fenofibrate group: specification 200mg/ grain, lot number 89396, French Li Bofuni drugmaker produces;
Cholesterol: specification biochemical reagents, 25g/ bottle, lot number: 070516, Tianjin recovery fine chemistry industry institute;
Sodium cholate: specification biochemical reagents, lot number: 20070525, Beijing chemical reagents corporation;
Adeps Sus domestica: You Zhe research department provides;
Serum total cholesterol (TC) assay test kit, lot number: 070501, Zhongsheng Beikong Biological Science & Technology Co., Ltd.;
Triglyceride (TG) assay test kit, lot number: 071831, Zhongsheng Beikong Biological Science & Technology Co., Ltd.;
HDL-C (HDL-cho) assay test kit, lot number: 070171, Zhongsheng Beikong Biological Science & Technology Co., Ltd.;
Low-density lipoprotein cholesterol (LDL-cho) assay test kit, lot number: 070171, Zhongsheng Beikong Biological Science & Technology Co., Ltd.'s product;
Gartanin: yellow acicular crystal (CHCl
3), mp 171-172 ℃.Lot number: 071003, self-control.
Instrument
Microplate reader: model PECAN A-5082, Austria SUNRISE company product.
2 experimental techniques
High lipid food compound method: reference literature adds 10% Adeps Sus domestica, 1% cholesterol and 0.3% sodium cholate in 88.7% normal feedstuff.Adeps Sus domestica is heated and dissolved, add cholesterol and sodium cholate, after stirring, pour in feedstuff, mix thoroughly, add appropriate warm water and mix thoroughly, be laid in square plate, the about 1.5cm of thickness, is divided into the fritter of 2cm * 3cm size with wallpaper cutter, place in 80 ℃ of thermostatic drying chambers and dry.
Dosage: according to each group dosage, the weight of animals, administration natural law, calculate requirement respectively, accurately weighed, first add a small amount of distilled water, grind evenly, then adding distil water is to desired concn.
Animal conforms after buying 3 days, is divided at random: Normal group by body weight; Hyperlipidemia model group; Positive control drug XUEZHIKANG JIAONANG group (240mg/kg); Positive control drug fenofibrate group (40mg/kg); Gartanin high dose group (80mg/kg), middle dosage group (40mg/kg) and low dose group (20mg/kg); Totally 7 groups, 12 every group.
In experimentation, normal control treated animal is raised with conventional feed, and other each treated animals are all raised with high lipid food.Laboratory animal every morning gastric infusion 1 time.Gavage volume is 20ml/kg.Normal group and hyperlipidemia model treated animal gavage distilled water, administration group gives respectively corresponding drug solution.Successive administration 2 weeks, on last 1 administration that night, animal fasting be can't help water 16 hours, and next day, eyeball was got blood 0.5ml, centrifugal (3000r/min) separation of serum; Adopt enzymic colorimetric to measure serum total cholesterol (TC) content, adopt enzymic colorimetric to measure serum triglycerides (TG) content, adopt phosphotungstic acid-magnesium precipitate method to measure serum High Density Lipoprotein Cholesterol (HDL-cho) content, adopt polyvinyel sulfate to measure serum low-density LP cholesterol (LDL-cho) content.Achievement data is added and subtracted standard deviation (x ± s) with mean and is represented, t-check between statistical procedures method employing group.
3 experimental results
Experimental result shows, mice is being raised with high lipid food modeling after 2 weeks continuously, the serum TC of model group animal, TG, the equal compared with normal matched group of LDL-cho content obviously raise, TC content Normal group is 3.16 ± 0.48mmol/L, and model group is 6.54 ± 0.84mmol/L (P < 0.01); TG content Normal group is 0.69 ± 0.20mmol/L, and model group is 0.85 ± 0.21mmol/L (P < 0.05); LDL-cho content Normal group is 0.30 ± 0.28mmol/L, and model group is 1.92 ± 1.09mmol/L (P < 0.01); Serum hdl-cho content of model group animal obviously reduces, and Normal group is 3.90 ± 1.63mmol/L, and model group is 2.40 ± 0.79mmol/L (P < 0.05); The ratio of the serum TC of model group animal and HDL-cho content (TC/HDL-cho) obviously raises, and Normal group is 0.90 ± 0.24, and model group is 2.89 ± 1.53 (P < 0.01); Result shows that hyperlipidemia animal model forms.
After administration 2 weeks, Gartanin 80mg/kg dosage treated animal serum TC content (5.53 ± 1.04mmol/L) is starkly lower than hyperlipidemia model group (6.54 ± 0.84mmol/L) (P < 0.05); Administration treated animal serum hdl-cho content (2.62 ± 1.88mmol/L) relatively has rising trend with hyperlipidemia model group, but without marked difference (P > 0.05); Administration treated animal serum LDL-cho content (1.58 ± 0.87mmol/L) relatively has reduction trend with hyperlipidemia model group, but without marked difference (P > 0.05); Administration treated animal serum TC/HDL-cho ratio (2.31 ± 1.18mmol/L) relatively has reduction trend with hyperlipidemia model group, but without marked difference (P > 0.05); Administration treated animal serum TG content and hyperlipidemia model group are relatively without marked difference.
Gartanin 40mg/kg dosage treated animal serum TC content (5.54 ± 1.05mmol/L) is starkly lower than hyperlipidemia model group (6.54 ± 0.84mmol/L) (P < 0.05); Administration treated animal serum TG, LDL-cho, HDL-cho content and TC/HDL-cho ratio are compared without marked difference with hyperlipidemia model group.
Gartanin 20mg/kg dosage treated animal serum TC, TG, LDL-cho, HDL-cho content and TC/HDL-cho ratio are compared without marked difference with hyperlipidemia model treated animal.
Above-mentioned result of the test shows, extracts the effect that Gartanin compound has reduction hyperlipidemia model mice serum TC content that obtains in Hazel Leaves.Each treated animal TC, TG, LDL-cho, HDL-cho content and TC/HDL-cho ratio are in Table 1.
The specific embodiment
The present invention can further illustrate by experimental example below.
The embodiment 1 of extracting method:
A. Corylus heterophylla Fisch corium farinosum is broken, under 30 ℃ of conditions, with 25 times of amount 95% ethanol extractions 3 times, be respectively 3h, 2h, 1h at every turn, filter merge extractive liquid;
B. on extracting solution step a being obtained, reclaim ethanol to without alcohol taste, be extracted with ethyl acetate, reclaim extract and obtain ethyl acetate extract.
C. ethyl acetate extract step b. being obtained is through silica gel column chromatography, 1) and petroleum ether-acetone (25-1: 1) eluant is chloroform-methanol (15-1:, collect gartanin compound part, reclaim solvent to dry, Gossypol recrystallized from chloroform obtains yellow acicular crystal product, mp 171-172 ℃, productive rate reaches 0.45%.
The embodiment 2 of extracting method:
A. Corylus heterophylla Fisch corium farinosum is broken, under 80 ℃ of conditions, with 20 times of amount 30% ethanol extractions 3 times, be respectively 3h, 2h, 1h at every turn, filter merge extractive liquid;
B. on extracting solution step a being obtained, reclaim ethanol to without alcohol taste, be extracted with ethyl acetate, reclaim extract and obtain ethyl acetate extract.
C. ethyl acetate extract step b. being obtained is through silica gel column chromatography, 1) and petroleum ether-acetone (25-1: 1) eluant is chloroform-methanol (15-1:, collect gartanin compound part, reclaim solvent to dry, Gossypol recrystallized from chloroform obtains yellow acicular crystal product, mp 171-172 ℃, productive rate reaches 0.5%.
The embodiment 3 of extracting method:
A. Corylus heterophylla Fisch corium farinosum is broken, under 45 ℃ of conditions, with 22 times of amount 55% ethanol extractions 3 times, be respectively 3h, 2h, 1h at every turn, filter merge extractive liquid;
B. on extracting solution step a being obtained, reclaim ethanol to without alcohol taste, be extracted with ethyl acetate, reclaim extract and obtain ethyl acetate extract.
C. ethyl acetate extract step b. being obtained is through silica gel column chromatography, 1) and petroleum ether-acetone (25-1: 1) eluant is chloroform-methanol (15-1:, collect gartanin compound part, reclaim solvent to dry, Gossypol recrystallized from chloroform obtains yellow acicular crystal product, mp 171-172 ℃, productive rate reaches 0.4%.
The embodiment 1 for preparing medicament:
Get gartanin compound 20g, add medical starch 280g, the two fully mixes, and makes 1000 capsules, and every heavy 0.3g, containing gartanin 20mg.
The embodiment 2 for preparing medicament:
Get gartanin compound 100g, add medical starch 200g, the two fully mixes, and makes 1000, and every heavy 0.3g, containing gartanin 100mg.
The embodiment 3 for preparing medicament:
Get gartanin compound 20g, add 1,2-PD 100ml, heating for dissolving,, be diluted with water to 1000ml, dress up 1000 bottles, every bottle of 1ml, containing gartanin20mg.
Claims (1)
- The application of 1.gartanin compound in preparation treatment hyperlipidemia medicine, described gartanin compound is monomeric compound, Chinese is 1,3,5,8-tetrahydroxy-2,4-bis-(3-methyl-2-butene base) ketone, this gartanin compound is as unique active component of preparation treatment hyperlipidemia medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910066864.2A CN101869559B (en) | 2009-04-24 | 2009-04-24 | Application of gartanin compound in preparing medicaments for treating hyperlipidemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910066864.2A CN101869559B (en) | 2009-04-24 | 2009-04-24 | Application of gartanin compound in preparing medicaments for treating hyperlipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101869559A CN101869559A (en) | 2010-10-27 |
| CN101869559B true CN101869559B (en) | 2014-01-15 |
Family
ID=42994767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910066864.2A Expired - Fee Related CN101869559B (en) | 2009-04-24 | 2009-04-24 | Application of gartanin compound in preparing medicaments for treating hyperlipidemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101869559B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102204942B (en) * | 2011-05-24 | 2012-12-05 | 黑龙江大学 | Method for extracting corylus heterophylla leaf flavone |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6730333B1 (en) * | 2002-10-30 | 2004-05-04 | Dbc, Llc | Nutraceutical mangosteen composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009013105A (en) * | 2007-07-04 | 2009-01-22 | Yoshihiro Futamura | Xanthone derivatives having collagen-increasing action, method for producing the same, cosmetics and food preparation comprising the derivatives |
-
2009
- 2009-04-24 CN CN200910066864.2A patent/CN101869559B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6730333B1 (en) * | 2002-10-30 | 2004-05-04 | Dbc, Llc | Nutraceutical mangosteen composition |
Non-Patent Citations (7)
| Title |
|---|
| JP特开2009-13105A 2009.01.22 |
| The suppressive effect of mangiferin with exercise on blood lipids in type 2 diabetes;Toshihiro Miura, et al.;《Biol. Pharm. Bull.》;20010930;第24卷(第9期);1091-1092 * |
| Toshihiro Miura, et al..The suppressive effect of mangiferin with exercise on blood lipids in type 2 diabetes.《Biol. Pharm. Bull.》.2001,第24卷(第9期),1091-1092. |
| 口山酮的调血脂及抗氧化作用;贾素洁 等;《湖南省生理科学学会2004年度学术年会》;20041231;45 * |
| 莽吉柿果皮化学成分及其生物活性研究;赵岩;《中国博士学位论文全文数据库》;20081231(第11期);64,94,121-150 * |
| 贾素洁 等.口山酮的调血脂及抗氧化作用.《湖南省生理科学学会2004年度学术年会》.2004,45. |
| 赵岩.莽吉柿果皮化学成分及其生物活性研究.《中国博士学位论文全文数据库》.2008,(第11期),64,94,121-150. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101869559A (en) | 2010-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105395919B (en) | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof | |
| CN102634441B (en) | A kind of preparation method of health-care vinegar | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN106923337A (en) | A kind of preparation method and applications of spirulina full agonist | |
| CN103120228A (en) | Black tea composition for adjusting blood fat and preparation method of black tea composition | |
| CN100556429C (en) | A kind of pharmaceutical composition that contains Fructus Vitis viniferae extract and preparation method thereof, purposes | |
| CN105983016B (en) | A pharmaceutical composition containing silybin | |
| CN1557842A (en) | Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof | |
| CN101664180A (en) | Health-care nutritional complexing agent with effect of and preparation method thereof | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN104027494A (en) | Traditional Chinese medicinal composition with effects of delaying senescence and protecting health | |
| CN101869559B (en) | Application of gartanin compound in preparing medicaments for treating hyperlipidemia | |
| CN101550125B (en) | Hazelnut element B, extracting method and pharmaceutical use thereof | |
| CN100337655C (en) | Medicine preparation for preventing and treating allergic rhinitis and compliance rhinitis | |
| CN101613340B (en) | Hazel endothelin and extracting method and drug application thereof | |
| CN105012826A (en) | Alpinia oxyphylla leaf extract and preparation method and application thereof | |
| CN104013669A (en) | Method for preparing cyclocarya paliurus total flavonoid with effect of reducing blood glucose | |
| CN100534461C (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and preparation method thereof | |
| CN108743840A (en) | A kind of Chinese medicine composition and preparation method thereof with auxiliary lipid-lowering function | |
| CN106038869B (en) | A kind of compound guava preparation and preparation method thereof | |
| CN101120969A (en) | Medicine for treating diabetes and its complications and preparing method thereof | |
| CN104970360A (en) | Health-care food for reducing blood lipid and preparation method of health-care food | |
| CN104758358A (en) | Medicine composite used for eczema and preparation method thereof | |
| CN110840950A (en) | Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury | |
| CN103735591B (en) | A kind of compositions of anti-peptic ulcer and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xing Hongcun Inventor after: Li Pingya Inventor after: Liu Jinping Inventor after: Lu Dan Inventor after: Xue Jianfei Inventor before: Li Pingya Inventor before: Liu Jinping Inventor before: Lu Dan Inventor before: Xue Jianfei |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140115 |